학술논문
63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID)
Document Type
Abstract
Author
Source
In Journal of Thoracic Oncology April 2021 16(4) Supplement:S729-S730
Subject
Language
ISSN
1556-0864